Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers
Conclusion: Homebound AHCT is safe and feasible with less than half of patients requiring inpatient admission. Patients required an average of two outpatient visits while receiving homebound care for blood products. Qualitative evaluations of the program by patients and caregivers were overwhelmingly positive. Based on these results we intend to expand the homebound program and investigate other potential biologic (microbiota diversity preservation) and economic benefits.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Landau, H. J., Shah, G. L., Reeds, M., Hilden, P., Andrejko, M., Applebaum, A., Batalha, J., Cazeau, N., Chung, D. J., Cortes, M., Gerber Jenkelowitz, J., Kiss, C., Devlin, S. M., Lestrange, N., Lynch, K., McElrath, C., Palumbo, D., Rodriguez, E. S., Scor Tags: 902. Health Services Research-Malignant Diseases: Poster I Source Type: research
More News: Amyloidosis | Bone Marrow Transplant | Cancer | Cancer & Oncology | Cancer Therapy | Clostridium Difficile | Diets | Environmental Health | Hematology | Myeloma | Nurses | Nursing | Nutrition | Sports Medicine | Statistics | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants